CIClarence Buddy Creech Ii

Clarence Buddy Creech Ii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Clarence Buddy Creech Ii has a total of 394 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Frequency of Asymptomatic Bordetella pertussis Colonization in Healthy Children and Family Members

    by Dakota Musgrave, Luke Keffer, Sandra M Yoder, Nicole Soper, C Buddy Creech

    Lay Summary: Non-human primate data suggest that acellular pertussis vaccines are successful in preventing pertussis disease but may not prevent asymptomatic colonization or transmission. Despite this, we found no evidence of asymptomatic colonization in a cohort of healthy children and their family members.

  • Open Access

    Transcriptomic and proteomic signatures following AS03-adjuvanted Influenza A/H7N9 vaccine

    by C. Buddy Creech, Kristen J. Steenbergen, Casey E. Gelber, Leigh M. Howard, Kevin L. Schey, Kristie Lindsey Rose, Sandra M. Yoder, Kathryn M. Edwards, Johannes B. Goll

    Introduction: Vaccines targeting avian influenza virus A/H7N9 are poorly immunogenic. While the immune responses can be improved with oil-in-water emulsion adjuvants such as Adjuvant System 03 (AS03), the cellular mechanisms underpinning the adjuvant effect are incompletely characterized and poorly understood. Methods: We enrolled 30 healthy adult participants and used RNA sequencing and quantitative proteomics to characterize the response to two doses of the influenza A/H7N9 vaccine, with and without AS03, in six immune cell types. These responses were compared to those seen after administration of an unadjuvanted seasonal in uenza A/H3N2 variant vaccine to identify signatures unique to adjuvanted influenza vaccines and correlated with later antibody responses. Transcriptomic and proteomic analyses revealed that. Results: AS03-adjuvanted vaccine was associated with upregulation of immune pathways in innate immune cells within 24h following vaccination for phagocytosis, antigen presentation and processing, inflammasome activation, NK-cell mediated cytotoxicity, IgA production, and interferon-response pathways. Moreover, while major histocompatibility complex (MHC I and II) upregulation was observed across multiple immune cell types, MHCII gene transcription was also increased in the neutrophil compartment, generating the hypothesis that neutrophils may play a more important role in antigen presentation than previously understood. Discussion: Taken together, these data provide a more complete mechanistic understanding of oil-in-water adjuvants and their role in enhancing the immune response for pandemic influenza preparedness. Clinical Trial Registration: https://clinicaltrials.gov/study/NCT02921997?term=NCT02921997&viewType , idientifier NCT02921997.

  • Open Access

    Population Pharmacokinetic Modeling and Target Attainment of Cefepime in Critically Ill Pediatric Patients

    by Stephanie L Rolsma, Marisa Blackman, Cole Beck, Ahmad Dbouk, Foday Morovia, Faith Glover, Gabriella Ess, Katelyn Dohler, Brian Bridges, Leena Choi, et al.

    Background: Cefepime dosing guidelines are well defined in healthy populations but have not been studied extensively in critically ill children who often have significant alterations in antibiotic pharmacokinetics (PK) and pharmacodynamics (PD). Cefepime dosing optimization is important for patient outcomes. Method: We prospectively enrolled critically ill children receiving cefepime. Plasma samples were collected at opportunistic time points. Cefepime plasma concentrations were measured by liquid-chromatography-tandem mass spectrometry. Population PK (popPK) analysis was conducted with a priori selected covariates. The final covariate model was used to perform probability of target attainment (PTA) analysis. Results: Data from 84 participants were analyzed. A 2-compartment with proportional error model was selected as the base model. Inclusion of weight and creatinine clearance (CrCl) improved model fit. Estimated breakpoints—the highest minimum inhibitory concentration with ≥90% pharmacokinetic target attainment—were 2-fold higher for 3-hour compared with 30-minute infusions for q8h dosing regimens. For q12h regimens, 3-hour infusions also yielded 2-fold higher breakpoints for the lowest target. Continuous compared with 3-hour infusions resulted in 4- to 16-fold higher breakpoints at the same daily dose at the higher targets. Increased CrCl led to reduced PTA. Conclusions: Given the variability observed in critically ill children, clinicians should consider incorporating therapeutic drug monitoring and popPK models to determine optimal dosing in this population. The use of extended infusions and more frequent or continuous dosing is beneficial for PK/PD target achievement, particularly for Pseudomonas aeruginosa and antimicrobial-resistant pathogens. Use of these strategies should be strongly considered in the pediatric critically ill population.


  • Open Access

    Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews

    by Paula M. Campbell, Gabriella J. Ess, Allison Lale, Kawsar R. Talaat, Elizabeth D. Barnett, Stephen I. Pelton, Elizabeth P. Schlaudecker, Mary Staat, Melissa S. Stockwell, Phillip S. LaRussa, et al.


  • Open Access

    Immunologic profiling of the infant immune response to whole-cell and acellular pertussis vaccines

    by C. Buddy Creech, Mariana Leguia, Johannes B. Goll, Leigh M. Howard, Antón Vila-Sanjurjo, Sandra Yoder, Diana Juarez, Alejandra Garcia-Glaessner, Casey E. Gelber, Natalia Jimenez-Truque, et al.

    Despite robust antibody responses, immunity induced by acellular pertussis vaccine (DTaP) wanes over time and risk of pertussis seems to be lower in children who receive whole-cell vaccine (DTP) as their first dose. To interrogate the early immunologic response to pertussis vaccine, we enrolled 56 healthy infants who received either DTP or DTaP at 2-, 4-, 6-, and 18-months of age. RNA-sequencing and ribosome profiling of PBMC were performed prior to vaccination (Day 1) and on either Day 2 or Day 8. Pathway enrichment analysis on Days 2 and 8 showed enrichment of TLR-signaling and FcϒR-mediated phagocytosis among DTP recipients. DTP also led to increases in IRAK-4 and IL-1ß. After booster vaccination, a higher frequency of PT-specific B-cells was observed in DTP- vs. DTaP recipients. These data provide insights into the early immunologic responses to pertussis vaccine and may guide next-generation pertussis vaccine development.


  • Open Access

    Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age

    by Christina A Rostad, James D Campbell, Grant C Paulsen, Sabine Schnyder Ghamloush, Wenqin Xu, Lingyi Zheng, M Juliana McElrath, Stephen C De Rosa, Bethany Girard, Rituparna Das, et al.

    Background: Cell-mediated immunity (CMI) may help protect against emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that are less susceptible to neutralizing antibodies. We present CMI data after the mRNA-1273 primary series in a subset of participants aged 6 months to 11 years from the phase 2/3 KidCOVE trial. Methods: T-cell responses were assessed after 2 doses of mRNA-1273 (6 months to 5 years, 25 μg; 6–11 years, 50 μg) or placebo administered 28 days apart. Magnitude, phenotype, and percentage of ancestral SARS-CoV-2 spike (S) protein T-cell responses to pooled peptides were assessed by intracellular cytokine staining and polyfunctionality analyses. Results: A total of 68 children aged 6 months to 11 years received either the 2-dose mRNA-1273 primary series or placebo (51 and 17, respectively) at 28-day interval. mRNA-1273 induced S-protein–specific CD4+ T-cell responses exhibiting a type 1 T helper (Th1)–biased profile at day 43 and day 209 compared with placebo. S-protein–specific CD8+ T-cell responses were less frequently detected in children <5 years and undetectable in those <2 years. Compared with placebo, mRNA-1273 induced higher frequencies of S-specific polyfunctional CD4+ T cells at day 43; frequencies declined but remained detectable at day 209. Correlation between Th1 CD4+ responses and neutralizing antibodies was observed across age groups following mRNA-1273 vaccination. Conclusions: The 2-dose mRNA-1273 primary series elicited robust and durable (≥ 6 months) Th1-biased CD4+ T-cell responses in children aged 6 months to 11 years. CD8+ T-cell responses varied by age. Clinical Trials Registration. NCT04796896.


  • A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18–45 years of age

    by Theresa E. Hegmann, Emmanuel B. Walter, Michael J. Smith, James Campbell, Hana M. El Sahly, Jennifer A. Whitaker, C. Buddy Creech, Irina V. Ustyugova, Ana P. Goncalvez, Aseem Pandey, et al.


  • Open Access

    Transcriptomic Biomarkers Associated With Microbiological Etiology and Disease Severity in Childhood Pneumonia

    by Derek J Williams, Shruti Gautam, C Buddy Creech, Natalia Jimenez, Evan J Anderson, Steven Bosinger, Tyler Grimes, Sandra R Arnold, Jonathan A McCullers, Johannes Goll, et al.

    Challenges remain in discerning microbiologic etiology and disease severity in childhood pneumonia. Defining host transcriptomic profiles during illness may facilitate improved diagnostic and prognostic approaches. Using whole blood ribonucleic acid sequencing from 222 hospitalized children with radiographic pneumonia and 45 age-matched controls, we identified differentially expressed genes that best identified children according to detected microbial pathogens (viral-only vs. bacterial-only and typical vs. atypical bacterial [+/- viral co-detection]) and an ordinal measure of phenotypic severity (moderate, severe, very severe). Overall, 135 (61%) children had viral-only detections, 15 (7%) had typical bacterial (+/- viral co-detections), and 26 (12%) had atypical bacterial (+/- viral co-detections). Eleven DE genes distinguished between viral-only and bacterial-only detections. Sixteen DE genes distinguished between atypical and typical bacterial detections (+/- viral co-detections). Nineteen DE genes distinguished between levels of pneumonia severity, including four genes also identified in the viral-only vs. bacterial-only model (IGHGP, PI3, CD177, RAP1GAP1) and four genes from the typical vs atypical bacterial model (PRSS23, IFI27, OLFM4, and ABO). We identified transcriptomic biomarkers associated with microbial detections and phenotypic severity in children hospitalized with pneumonia. These DE genes are promising candidates for validation and translation into diagnostic and prognostic tools.


  • Open Access

    Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis

    by Stephanie L Rolsma, Andrew Sokolow, Pratish C Patel, Katherine Sokolow, Natalia Jimenez-Truque, William H Fissell, Vivian Ryan, Carl M Kirkpatrick, Roger L Nation, Kenan Gu, et al.

    Background: Patients with cystic fibrosis (CF) experience recurrent bacterial pulmonary exacerbations. Management of these infections is increasingly challenging due to decreased antimicrobial susceptibility to β-lactam antibiotics. The pharmacokinetics (PK) of these agents are inadequately characterized in patients with CF. Methods: This study enrolled 155 pediatric and adult participants with CF who were receiving the following β-lactam antibiotics: cefepime (n = 82), meropenem (n = 42), or piperacillin-tazobactam (n = 31). Opportunistic blood samples were obtained during hospitalization. Population PK analysis was conducted via nonlinear mixed effects modeling. Clinical and demographic characteristics were evaluated as potential covariates. Monte Carlo simulations were performed to evaluate the probability of target attainment (PTA) for different dosing regimens. Results: Estimated creatinine clearance and total or lean body weight affected the PK of cefepime and meropenem. No covariates were identified for piperacillin and tazobactam. In the cefepime group, a 3-hour infusion achieved a higher PTA than a 0.5-hour infusion for all participants. Estimated breakpoints—the respective minimum inhibitory concentration up to which ≥90% of patients are predicted to reach a PK/pharmacodynamic target—were 2- to 4-fold higher in pediatric participants receiving a 3- vs 0.5-hour infusion. In the meropenem group, increased creatinine clearance led to reduced PTA. In the piperacillin-tazobactam group, total daily dose and mode of administration were principal drivers of PTA. Conclusions: Standard dosing regimens fail to achieve specific minimum inhibitory concentration targets in patients with CF. Therefore, clinicians should incorporate local antibiograms and PK models to determine optimal dosing. Further PK optimization to account for interindividual differences could be achieved by real-time β-lactam therapeutic drug monitoring.